I sat down with Dr. Yasir Elamin to get his thoughts on his abstract presented at ASCO regarding patient reported outcomes and health-related quality of life with Taletrectinib in advanced ROS1 non-small cell lung cancer (NSCLC) abstract from the Trust-II Study.
